Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

2.709 -0.041 (-1.48%)
Streaming Delayed Price Updated: 11:41 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Cp

< Previous 1 2 3 4 5 Next >
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Why Arbutus Biopharma's Stock Is Trading Lower Today
Arbutus Biopharma's Stock Price And Volume Action Arbutus Biopharma's (NASDAQ: 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Bullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ: 
Via Benzinga
Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Arbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress... 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
24 Stocks Moving in Friday's Pre-Market Session
Gainers Senseonics Holdings, Inc. (NYSE: SENS) rose 37.1% to $2.81 in pre-market trading after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
28 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares rose 28.5% to $0.7451 in pre-market trading after the company reported better-than-expected Q1 sales. Bionano Genomics, Inc. (NASDAQ:... 
Via Benzinga
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs. Here is a look back at the week in SPACs for... 
Via Benzinga
Arbutus Biopharma (ABUS) Q1 2021 Earnings Call Transcript
ABUS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning. The SPAC Deal:... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.